ERBB2 and breast carcinoma: Presently, the 5-year survival rate is increasing up to 90% in HER2+ early breast cancer treated with chemotherapy and combined or dual mAbs trastuzumab and pertuzumab therapies, as they show complementary mechanisms of action [5].